(Q39438124)

12 September 2017

Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human (English)

1 reference

12 September 2017

1 reference

1 reference

Joanna Parkinson

1

1 reference

12 September 2017

Sandra A G Visser

2

1 reference

12 September 2017

Philip Jarvis

3

1 reference

12 September 2017

Chris Pollard

4

1 reference

12 September 2017

Jean-Pierre Valentin

5

1 reference

12 September 2017

James W T Yates

6

1 reference

12 September 2017

Lorna Ewart

7

1 reference

12 September 2017

6 April 2013

1 reference

Journal of Pharmacological and Toxicological Methods

12 September 2017

1 reference

12 September 2017

68

1 reference

12 September 2017

3

1 reference

12 September 2017

357-366

1 reference

Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Drugs, hERG and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

A step towards characterisation of electrophysiological profile of torsadogenic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

The impact of drug-induced QT interval prolongation on drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

The QT interval and torsade de pointes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

QTc interval (cardiac repolarization): lengthening after meals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

A novel approach to data processing of the QT interval response in the conscious telemetered beagle dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Non-invasive telemetric electrocardiogram assessment in conscious beagle dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

hERG potassium channels and cardiac arrhythmia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Estimating impossible curves using NONMEM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

The significance of QT interval in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

An improved method to correct the QT interval of the electrocardiogram for changes in heart rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

Dofetilide block involves interactions with open and inactivated states of HERG channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2013.03.007

10.1016/J.VASCN.2013.03.007

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference